Webinar
Induced pluripotent stem cell (iPSC) technology integrates human biology to enhance drug safety and efficacy predictions. But achieving scalability and consistency in high-throughput cardiac screening applications is difficult — until now.
“Advancing High-Throughput Cardiac Screening With Physiologically Relevant 3D iPSC-Based Models” offers an inside look at Ncyte® Heart in a Box™ and how it enables scalable, consistent and human-relevant cardiac screening that improves predictive power.
Watch the replay now for:
- Insights into enhancing drug discovery scalability with 10-billion-cell batches of Ncyte® NHP-C vCardiomyocytes
- Insider knowledge of how Ncyte® Heart in a Box™ enables 1,500-compound-per-day screening with minimal batch variability
- Tips for applying Heart in a Box™ for cardiotoxicity testing and disease modeling
- A behind-the-scenes look at how Heart in a Box™ helped Leiden University Medical Center (LUMC) develop a 3D cardiac microtissue model of catecholaminergic polymorphic ventricular tachycardia (CPVT)
Meet the Speakers
.png?width=200&height=229&name=Mariana%20(1).png)
Mariana Argenziano, Ph.D.
Associate Director Manufacturing Technology at Ncardia
Dr. Argenziano earned her Ph.D. in molecular biology from the University of San Martín in Buenos Aires and has over a decade of experience in stem cell biology, having conducted research at several leading universities in the United States. Her expertise spans iPSC differentiation into cardiac, neuronal and other cell types, as well as disease modeling and biobank development.
At Ncardia, Mariana has played a pivotal role in establishing and scaling iPSC manufacturing procedures, ensuring their availability for large-scale applications. Her work focuses on producing high-quality, reproducible cell batches to drive advancements in disease modeling, drug screening and tissue engineering.
Richard Davis, Ph.D.
Assistant Professor at the Leiden University Medical Center (LUMC)
Richard earned his Ph.D. from Monash University and has received prestigious awards throughout his career, including an ERC Starting Grant and Dutch Vidi award. Next to his leadership at LUMC he is a member of the Leiden reNEW node for the Novo Nordisk Foundation Center for Stem Cell Medicine. His research focuses on modeling cardiovascular diseases using human pluripotent stem cells, with models ranging from 2D cardiomyocyte cultures to complex 3D systems integrating vascular, stromal and immune cells. He has pioneered high-throughput pipelines for disease modeling, drug screening and AI-driven analysis, aiming to uncover treatments for rare genetic heart diseases.
This is your opportunity to uncover the secret to scalable, human-relevant research that will lead to safer, more effective therapies in a fraction of the time.